ERBB2 and breast cancer: The Katherine Clinical Trial evaluated the efficacy and safety of T-DM1 (trastuzumab, covalently linked through a molecular bond to the antimicrotubule chemotherapy emtansine) versus trastuzumab alone as adjuvant therapy in patients with HER2-positive BC with residual disease after NAC.